Final analysis of the placebo-controlled randomised phase 3 IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC) Meeting Abstract
| Authors: | Harbeck, N.; Barrios, C.; Zhang, A.; Saji, S.; Jung, K. H.; Hegg, R.; Köhler, A.; Sohn, J. H.; Iwata, H.; Telli, M.; Boileau, J. F.; Punie, K.; Dieterich, M.; Assaf, Z.; Xu, T.; Hermoso, M. L.; Shearer-Kang, E.; Molinero, L.; Chui, S.; Mittendorf, E. |
| Abstract Title: | Final analysis of the placebo-controlled randomised phase 3 IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC) |
| Meeting Title: | 36. Deutscher Krebskongress - Fortschritt gemeinsam gestalten |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 47 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Feb 21-24 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2024-02-01 |
| Start Page: | 30 |
| Language: | English |
| ACCESSION: | WOS:001332646400059 |
| PROVIDER: | wos |
| DOI: | 10.1159/000535363 |
| Notes: | Meeting Abstract: 175 -- 'The 36th German Cancer Congress - Building Progress Together' -- Located in the section 'Breast Cancer' -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work